Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Mechanism CD20 modulators(B-lymphocyte antigen CD20 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date ID (30 Nov 2022), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Non-Hodgkin Lymphoma | ID | 30 Nov 2022 |